## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.40 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($168.23)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan**
- Source: Finviz | 20260105T140810 | Bullish | Relevance: 100%
- Corewell Health and Quest Diagnostics have finalized a joint venture, named Diagnostic Lab of Michigan, LLC, to enhance laboratory services in Michigan. Quest will hold 51% equity, while Corewell Health will retain 49%. The partnership also involves Quest's Collaborative Lab Solutions providing hospital lab management services for all 21 Corewell Health hospitals, with a new state-of-the-art facility expected to open in 2027.

**2. Corewell Health, Quest Diagnostics form joint venture**
- Source: Modern Healthcare News | 20260105T120600 | Bullish | Relevance: 100%
- Corewell Health and Quest Diagnostics have finalized a joint venture, where Quest will manage supply chain and other services for all Corewell inpatient and outpatient hospital labs. This agreement strengthens their partnership in the healthcare sector.

**3. What You Need To Know Ahead of Quest Diagnostics' Earnings Release**
- Source: Palmetto Grain Brokerage | 20260105T120759 | Somewhat-Bullish | Relevance: 100%
- Quest Diagnostics (DGX) is set to announce its Q4 2025 earnings, with analysts projecting an adjusted EPS of $2.36, a 5.8% increase year-over-year. The company has consistently beaten Wall Street's bottom-line estimates and raised its full-year guidance in Q3 2025. Despite recent stock performance lagging the S&P 500, analysts have a "Moderate Buy" rating with a potential upside of 14.8%.

**4. NeoGenomics Adds Diagnostics Executive Jack Kenny To Board**
- Source: Pulse 2.0 | 20260104T090700 | Neutral | Relevance: 64%
- NeoGenomics has appointed John P. "Jack" Kenny, a diagnostics and laboratory services veteran, to its Board of Directors. Kenny brings over 30 years of experience to the role as NeoGenomics aims to expand its oncology testing services, particularly in next-generation sequencing (NGS) and minimal residual disease (MRD) testing. His appointment strengthens the board's expertise in a rapidly evolving field, replacing Alison Hannah, MD, who served for over a decade.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($1.18M) |
| Sells | 5 ($3.52M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Insider selling cluster: $3.5M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.40 suggests fair value with growth premium. Forward P/E 16.7x stretched relative to 6% growth. Insider selling cluster ($3.5M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.4B |
| Beta | 0.64 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.40 |
| Forward P/E | 16.7 |
| Current P/E | 17.7 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -2.6% (minimal 5-day change). Below STRENGTH zone by 6.6pp (needs >4.0% for momentum thesis). Underperforming sector by 3.2pp, stock-specific weakness. Below SMA200 (0.98x), long-term trend not supportive. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.63% (CS: 15) | Weak |
| RSI_14 | 33.3 | Neutral |
| MACD Histogram | -0.35 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 0.957x | Below |
| vs SMA200 | 0.978x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $173.41
- **Stop Loss:** $168.23 (3.0% risk)
- **Target:** $183.77 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 166
- **Position Value:** $28,786.06
- **Portfolio %:** 28.79%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*